Tildrakizumab for Psoriasis
What You Need to Know Before You Apply
What is the purpose of this trial?
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.
Will I have to stop taking my current medications?
The trial requires that you have not taken systemic immunosuppressives (medications that suppress the immune system) in the last 4 weeks. If you are on such medications, you may need to stop them before participating.
Is Tildrakizumab safe for humans?
How is the drug Tildrakizumab different from other psoriasis treatments?
Tildrakizumab is unique because it specifically targets the p19 subunit of interleukin-23, a protein involved in inflammation, without affecting interleukin-12, which is different from some other treatments that target both. This specificity may lead to fewer side effects and improved effectiveness for moderate-to-severe chronic plaque psoriasis.15678
What data supports the effectiveness of the drug Tildrakizumab for treating psoriasis?
Tildrakizumab has been shown to be effective in treating moderate-to-severe chronic plaque psoriasis, as demonstrated by positive results from phase III clinical trials (reSURFACE 1 and reSURFACE 2) where it was found to be superior to placebo and etanercept. It works by targeting a specific part of the immune system (interleukin-23 p19) that is involved in the development of psoriasis.12579
Who Is on the Research Team?
Raymond Cho, MD, PhD
Principal Investigator
University of California, San Francisco
Are You a Good Fit for This Trial?
This trial is for adults over 18 with moderate to severe psoriasis, affecting more than 5% of their body. It's not suitable for those on systemic immunosuppressives in the last month, pregnant or breastfeeding individuals, people with severe immune deficiencies, active tuberculosis or other serious infections, and anyone with an active systemic cancer.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive tildrakizumab and undergo biopsy and blood sample collection for molecular profiling
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Tildrakizumab
Tildrakizumab is already approved in European Union, United States for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, San Francisco
Lead Sponsor
Sun Pharmaceutical Industries Limited
Industry Sponsor
Dilip Shanghvi
Sun Pharmaceutical Industries Limited
Chief Executive Officer since 1993
Majored in Cellular and Molecular Biology at the University of Michigan – Ann Arbor
Dr. Azadar H. Khan
Sun Pharmaceutical Industries Limited
Chief Medical Officer since 2023
MD from a recognized institution